

Appln No.: 10/646,436  
Amendment Dated: March 23, 2006  
Reply to Office Action of January 9, 2006

**Amendments to the Claims:**

This listing of claims will replace all prior versions, and listings, of claims in the application:

**Listing of Claims:**

1-3 (canceled)      An RNA molecule having a sequence effective to mediate degradation or block translation of mRNA that is the transcriptional product of a target gene, wherein the target gene encodes clusterin, and the RNA molecule comprises a sequence of bases complementary to the gene for human clusterin.

4. (currently amended)      An RNA molecule having a sequence effective to mediate degradation or block translation of mRNA that is the transcriptional product of a target gene, wherein the target gene encodes clusterin, and the RNA molecule comprises a sequence of bases complementary to the gene for human clusterin, ~~The RNA molecule of claim 3,~~ wherein the RNA molecule consists of a sequence selected from among Seq ID Nos 1 to 16.

5-9. (canceled)

10. (currently amended)      A pharmaceutical composition comprising an RNA molecule having a length of less than 49 bases and having a sequence effective to mediate degradation or block translation of mRNA that is the transcriptional product of a target gene, wherein the target gene encodes clusterin, and the RNA molecule comprises a sequence of bases complementary to the gene for human clusterin, wherein the RNA molecule consists of a sequence selected from among Seq ID Nos 1 to 16 together with a pharmaceutically acceptable carrier.

11. (original)      The pharmaceutical composition of claim 10, wherein the pharmaceutically acceptable carrier is a sterile injectable solution.

12-30.

31. (currently amended)      An RNA molecule having a sequence effective to mediate degradation or block translation of mRNA that is the transcriptional product of a target gene, wherein the target gene encodes clusterin, and the RNA molecule comprises a sequence of bases complementary to the gene for human clusterin ~~The RNA molecule of claim 1,~~ wherein the RNA molecule comprises a sequence as defined by Seq. ID No. 10.

Appln No.: 10/646,436  
Amendment Dated: March 23, 2006  
Reply to Office Action of January 9, 2006

32. (canceled)

33. (currently amended) A pharmaceutical composition comprising an RNA molecule having a length of less than 49 bases and having a sequence effective to mediate degradation or block translation of mRNA that is the transcriptional product of a target gene, wherein the target gene encodes clusterin, and the RNA molecule comprises a sequence of bases complementary to the gene for human clusterin, together with a pharmaceutically acceptable carrier ~~The pharmaceutical composition of claim 10,~~ wherein the RNA molecule comprises a sequence as defined by Seq. ID No. 10.

34. (canceled)